Clik here to view.
研究调查采用Masimo SpHb®无创连续血红蛋白监护的患者血液管理项目对术后癌症患者的效应
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天发布了《输血》(Blood Transfusion)发表的一项研究结果，该研究中，意大利雷焦艾米利亚省Azienda USL-IRCCS的Lucia Merolle博士及其同事研究应用患者血液管理项目（包括采用Masimo...
View ArticleClik here to view.
BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the...
BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
COVID-19 Highlights Role of Early Detection in Fighting Threatening Diseases,...
BEIJING The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, according to Sizhen...
View ArticleClik here to view.
NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with...
EMERYVILLE, Calif. NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market, announces the signing of an agreement...
View ArticleClik here to view.
BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare...
CAMBRIDGE, Mass. & BEIJING BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today...
View ArticleClik here to view.
Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual...
TEL AVIV, Israel & MELBOURNE, Australia Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today...
View ArticleClik here to view.
Humanigen Australia Proprietary Limited成立，旨在促进亚太区增长计划
加州伯灵格姆 (美国商业资讯)–Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”)是一家临床阶段生物制药公司，专注于通过其先导候选药物lenzilumab™预防和治疗称为“细胞因子风暴”的过度免疫反应，Humanigen今天宣布成立Humanigen Australia Proprietary Limited (“Humanigen Australia...
View ArticleClik here to view.
Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for...
GUANGZHOU, China Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin®...
View ArticleClik here to view.
MEDIROM Healthcare Technologies Inc. Announces Filing of Registration...
TOKYO MEDIROM Healthcare Technologies Inc. (“MEDIROM”), the healthcare company which runs branded relaxation salons in Japan, today announced it has publicly filed a registration statement on Form...
View ArticleClik here to view.
アジア太平洋地域での成長計画を促進すべくHumanigen Australia Proprietary Limitedを設立
米カリフォルニア州バーリンゲーム （ビジネスワイヤ） — 「サイトカインストーム」と呼ばれる過剰な免疫反応に対する当社の主力治療薬候補レンジルマブ（lenzilumab™）による予防と治療に傾注する臨床段階のバイオ製薬企業であるヒューマニゲン（NASDAQ: HGEN）は本日、Humanigen Australia Proprietary Limited（「Humanigen...
View ArticleClik here to view.
患者安全运动基金会推出新的承诺模式，以支持到2030年实现可预防的患者死亡人数为零的使命
加州尔湾 (美国商业资讯)–全世界每年有超过480万患者因可预防的医疗差错而丧生。全球非营利组织患者安全运动基金会(PSMF)致力于到2030年实现可预防医疗差错的患者死亡人数为零，并为医院和医疗机构推出改进的承诺模式，以帮助实现其目标。...
View ArticleClik here to view.
患者安全運動財団が2030年までに予防可能な患者死亡ゼロを達成するとの使命を支える新コミットメントモデルを発表
米カリフォルニア州アーバイン （ビジネスワイヤ） — 世界では毎年、480万人以上の患者が予防可能な医療過誤により命を落としています。世界的な非営利団体である患者安全運動財団（PSMF）は、2030年までに予防可能な患者死亡ゼロの達成を約束しており、その目標を実現するために病院・医療機関向けの改訂版コミットメントモデルを発表しました。...
View ArticleClik here to view.
Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early...
BEIJING Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests,...
View ArticleClik here to view.
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX®...
ALAMEDA, Calif. Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of...
View ArticleClik here to view.
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc....
View ArticleClik here to view.
Heartseed Named “Healthcare Company of the Year 2020” by Healthcare Insights...
TOKYO Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocyte spheroids for the treatment of heart failure (hereinafter HF), today announced...
View ArticleClik here to view.
联拓生物宣布获得Infigratinib在中国大陆开展治疗针对伴有FGFR2基因扩增的局部晚期或转移性胃癌或胃食管结合部腺癌患者的2a期临床试验批件
上海和普林斯顿（新泽西州） (美国商业资讯)– 联拓生物，一家专注于为中国和亚洲其他主要市场的患者带来颠覆性药物的生物制药公司，今日宣布已获得中国国家药品监督管理局（NMPA）药品审评中心（CDE）关于Infigratinib的2a期临床试验批件。Infigratinib是一种潜在的用于治疗伴有FGFR2基因扩增的局部晚期或转移性胃癌或胃食管结合部腺癌的末线治疗方式。 联拓生物已获得QED...
View ArticleClik here to view.
LianBio Announces Clearance to Initiate in China the Phase 2a Trial of...
SHANGHAI & PRINCETON, N.J. LianBio, a biotechnology company focused on bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that the Center...
View ArticleClik here to view.
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified...
VANCOUVER, British Columbia Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has...
View ArticleClik here to view.
LUCA Science Announces Joint Research With Division of Cardiology, Field of...
TOKYO LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the Division of Cardiology, Field of...
View Article